Cargando…
Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
Acute myeloid leukaemia (AML) is an aggressive cancer with 50–75% of patients relapsing even after successful chemotherapy. The role of the bone marrow microenvironment (BMM) in protecting AML cells from chemotherapeutics and causing consequent relapse is increasingly recognised. However the role th...
Autores principales: | O’ Reilly, Eimear, Dhami, Sukhraj Pal S., Baev, Denis V., Ortutay, Csaba, Halpin-McCormick, Anna, Morrell, Ruth, Santocanale, Corrado, Samali, Afshin, Quinn, John, O’Dwyer, Michael E, Szegezdi, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202320/ https://www.ncbi.nlm.nih.gov/pubmed/30361682 http://dx.doi.org/10.1038/s41598-018-33982-y |
Ejemplares similares
-
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011) -
Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo
por: Hou, Jue, et al.
Publicado: (2017) -
Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness
por: Erbayraktar, Zubeyde, et al.
Publicado: (2016) -
Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles
por: Rojas-Prats, Elisa, et al.
Publicado: (2021) -
Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)